CG Oncology (CGON) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $59.85, -3.25% vs the prior close of $61.86.
- Volume 1.08M shares, 1.2x its 50-day average.
- New SEC filings: 144 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
CGON slides 3.2% to $59.85, a 3-month low. Closed at $59.85, -3.25% vs the prior close of $61.86. Day range $59.42–$62.00, opened at $61.86.
CGON daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CGON slides 3.2% to $59.85, a 3-month low
- Closed at $59.85, -3.25% vs the prior close of $61.86. Day range $59.42–$62.00, opened at $61.86.
- Volume was 1.08M shares, 1.2x its 50-day average of 880.17K.
- Price is -17.2% vs its 50-day average ($72.28) and -8.1% vs its 200-day average ($65.10).
- 52-week range $35.80–$80.97; today's close sits at 53% of that range, 26.1% below the 52-week high.
Oct 15, 2026 — CGON ends flat (+0.0%) to $61.86
- Closed at $61.86, +0.03% vs the prior close of $61.84. Day range $60.96–$63.24, opened at $62.70.
- Volume was 1.19M shares, 1.4x its 50-day average of 874.89K.
- Price is -14.8% vs its 50-day average ($72.58) and -4.8% vs its 200-day average ($65.00).
- 52-week range $35.80–$80.97; today's close sits at 58% of that range, 23.6% below the 52-week high.
Oct 14, 2026 — CGON dips 0.9% to $61.84, a 3-month low, 3 down days in a row
- Closed at $61.84, -0.90% vs the prior close of $62.40. Day range $61.27–$63.44, opened at $62.48.
- Volume was 1.10M shares, 1.3x its 50-day average of 870.55K.
- Price is -15.0% vs its 50-day average ($72.79) and -4.7% vs its 200-day average ($64.89).
- 52-week range $35.80–$80.97; today's close sits at 58% of that range, 23.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CGON dips 1.2% to $62.40
- Closed at $62.40, -1.16% vs the prior close of $63.13. Day range $61.52–$63.85, opened at $61.92.
- Volume was 1.19M shares, 1.4x its 50-day average of 859.30K.
- Price is -14.5% vs its 50-day average ($72.98) and -3.7% vs its 200-day average ($64.78).
- 52-week range $35.80–$80.97; today's close sits at 59% of that range, 22.9% below the 52-week high.
Oct 12, 2026 — CGON dips 1.1% to $63.13
- Closed at $63.13, -1.08% vs the prior close of $63.82. Day range $62.68–$64.15, opened at $63.43.
- Volume was 660.60K shares, 0.8x its 50-day average of 857.31K.
- Price is -13.7% vs its 50-day average ($73.11) and -2.4% vs its 200-day average ($64.67).
- 52-week range $35.80–$80.97; today's close sits at 61% of that range, 22.0% below the 52-week high.
Oct 9, 2026 — CGON rises 0.9% to $63.82
- Closed at $63.82, +0.89% vs the prior close of $63.26. Day range $62.88–$65.18, opened at $62.97.
- Volume was 516.50K shares, 0.6x its 50-day average of 857.71K.
- Price is -12.9% vs its 50-day average ($73.27) and -1.1% vs its 200-day average ($64.55).
- 52-week range $35.80–$80.97; today's close sits at 62% of that range, 21.2% below the 52-week high.
Oct 8, 2026 — CGON rises 1.4% to $63.26
- Closed at $63.26, +1.41% vs the prior close of $62.38. Day range $61.11–$63.71, opened at $61.65.
- Volume was 910.30K shares, 1.1x its 50-day average of 861.59K.
- Price is -13.9% vs its 50-day average ($73.46) and -1.8% vs its 200-day average ($64.44).
- 52-week range $35.80–$80.97; today's close sits at 61% of that range, 21.9% below the 52-week high.
Oct 7, 2026 — CGON dips 2.0% to $62.38, a 3-month low
- Closed at $62.38, -1.98% vs the prior close of $63.64. Day range $61.90–$63.64, opened at $62.68.
- Volume was 621.80K shares, 0.7x its 50-day average of 873.87K.
- Price is -15.2% vs its 50-day average ($73.58) and -3.0% vs its 200-day average ($64.32).
- 52-week range $35.80–$80.97; today's close sits at 59% of that range, 23.0% below the 52-week high.
Oct 6, 2026 — CGON slides 7.4% to $63.64, a 3-month low
- Closed at $63.64, -7.38% vs the prior close of $68.71. Day range $63.19–$69.17, opened at $69.17.
- Volume was 774.40K shares, 0.9x its 50-day average of 881.18K.
- Price is -13.7% vs its 50-day average ($73.78) and -0.9% vs its 200-day average ($64.19).
- 52-week range $35.80–$80.97; today's close sits at 62% of that range, 21.4% below the 52-week high.
Oct 5, 2026 — CGON rises 2.0% to $68.71
- Closed at $68.71, +1.97% vs the prior close of $67.38. Day range $65.71–$68.95, opened at $67.60.
- Volume was 788.40K shares, 0.9x its 50-day average of 872.78K.
- Price is -7.1% vs its 50-day average ($73.98) and +7.3% vs its 200-day average ($64.06).
- 52-week range $35.80–$80.97; today's close sits at 73% of that range, 15.1% below the 52-week high.
Oct 2, 2026 — CGON dips 1.4% to $67.38
- Closed at $67.38, -1.42% vs the prior close of $68.35. Day range $66.61–$69.73, opened at $69.35.
- Volume was 1.54M shares, 1.8x its 50-day average of 862.69K.
- Price is -8.9% vs its 50-day average ($73.99) and +5.4% vs its 200-day average ($63.91).
- 52-week range $35.80–$80.97; today's close sits at 70% of that range, 16.8% below the 52-week high.
CGON latest news & SEC filings
Every SEC filing by or about CGON in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Post Leonard E converted options/RSUs into 1,000 shares at $0.60 (≈$600) on Sep 15, 2026; now holds 1,000
- Post Leonard E sold 1,000 shares at $72.98 (≈$72.98K) on Sep 15, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$79.06M (prior year -$41.43M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.90 (prior year -$0.54) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade CGON
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Feb 27, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.52% (largest 7.4%).
- Liquidity: about 1.08M shares (≈$64.90M) trade per day on average.
- 52-week position: $59.85 vs a range of $35.80–$80.97 (53% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Leonard E Post sold 1,000 shares on Sep 15, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 8, 2026.
- Share count: 88.64M shares outstanding (Aug 5, 2026), +16.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CGON market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 61.86 | 62.00 | 59.42 | 59.85 | 1.08M |
| Oct 15, 2026 | 62.70 | 63.24 | 60.96 | 61.86 | 1.19M |
| Oct 14, 2026 | 62.48 | 63.44 | 61.27 | 61.84 | 1.10M |
| Oct 13, 2026 | 61.92 | 63.85 | 61.52 | 62.40 | 1.19M |
| Oct 12, 2026 | 63.43 | 64.15 | 62.68 | 63.13 | 660.60K |
| Oct 9, 2026 | 62.97 | 65.18 | 62.88 | 63.82 | 516.50K |
| Oct 8, 2026 | 61.65 | 63.71 | 61.11 | 63.26 | 910.30K |
| Oct 7, 2026 | 62.68 | 63.64 | 61.90 | 62.38 | 621.80K |
| Oct 6, 2026 | 69.17 | 69.17 | 63.19 | 63.64 | 774.40K |
| Oct 5, 2026 | 67.60 | 68.95 | 65.71 | 68.71 | 788.40K |
| Oct 2, 2026 | 69.35 | 69.73 | 66.61 | 67.38 | 1.54M |
| Oct 1, 2026 | 70.38 | 71.27 | 68.32 | 68.35 | 984.90K |
| Sep 30, 2026 | 70.34 | 73.16 | 69.23 | 70.89 | 1.33M |
| Sep 29, 2026 | 69.56 | 70.68 | 68.26 | 70.52 | 1.04M |
| Sep 28, 2026 | 66.96 | 69.94 | 66.01 | 69.61 | 1.76M |
| Sep 25, 2026 | 69.32 | 70.05 | 66.76 | 67.15 | 1.18M |
| Sep 24, 2026 | 73.10 | 73.44 | 68.15 | 68.76 | 1.44M |
| Sep 23, 2026 | 76.87 | 77.79 | 71.86 | 73.36 | 830.90K |
| Sep 22, 2026 | 78.31 | 80.63 | 76.25 | 77.74 | 1.64M |
| Sep 21, 2026 | 75.74 | 78.46 | 74.22 | 78.25 | 1.11M |
About CG Oncology
CG Oncology (CGON) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in DALLAS, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1991792.
CGON board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Susan E Graf | Director | Jun 5, 2026 |
| Arthur Kuan | Chief Executive Officer | Apr 16, 2026 |
| Brian Guan-Chyun Liu | Director | Jun 29, 2026 |
| James Mulay | Director | Jul 14, 2026 |
| Leonard E Post | Director | Sep 17, 2026 |
| Christina Rossi | Director | Jun 5, 2026 |
| Victor Edward Jr Tong | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ambaw Bellete | President and COO | Apr 16, 2026 |
| James M. Detore | Chief Financial Officer | Apr 16, 2026 |
| Vijay Kasturi | Chief Medical Officer | Apr 16, 2026 |
| Arthur Kuan | Chief Executive Officer | Apr 16, 2026 |
| Joshua F. Patterson | See Remarks | Apr 16, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Leonard E Post | Sale | 1,000 | $72.98 |
| Sep 15, 2026 | Leonard E Post | Sale | 1,000 | $72.98 |
| Sep 15, 2026 | Leonard E Post | Sale | 1,000 | $72.98 |
| Sep 15, 2026 | Leonard E Post | Sale | 1,000 | $72.98 |
| Aug 14, 2026 | Leonard E Post | Sale | 1,000 | $74.54 |
| Aug 14, 2026 | Leonard E Post | Sale | 1,000 | $74.54 |
| Aug 14, 2026 | Leonard E Post | Sale | 1,000 | $74.54 |
| Aug 14, 2026 | Leonard E Post | Sale | 1,000 | $74.54 |
| Jul 15, 2026 | Leonard E Post | Sale | 1,000 | $71.17 |
| Jul 15, 2026 | Leonard E Post | Sale | 1,000 | $71.17 |
| Jul 15, 2026 | Leonard E Post | Sale | 1,000 | $71.17 |
| Jul 15, 2026 | Leonard E Post | Sale | 1,000 | $71.17 |
| Jul 10, 2026 | James Mulay | Sale | 24,165 | $75.16 |
| Jul 10, 2026 | James Mulay | Sale | 24,165 | $75.16 |
| Jul 10, 2026 | James Mulay | Sale | 24,165 | $75.16 |
CGON financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-161.00M | -2.08 | $-132.35M |
| Dec 31, 2024 | — | $-88.04M | -1.41 | $-78.71M |
| Dec 31, 2023 | — | $-48.61M | -15.65 | $-45.68M |
Latest balance sheet: total assets $1.09B, total liabilities $56.54M, cash $19.64M (as of Jun 30, 2026).
CGON earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $74.85 |
| May 8, 2026 | 8-K Item 2.02 (results) | $69.62 |
| Feb 27, 2026 | 8-K Item 2.02 (results) | $58.80 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $41.01 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $24.85 |
| May 13, 2025 | 8-K Item 2.02 (results) | $24.18 |
| Mar 28, 2025 | 8-K Item 2.02 (results) | $26.42 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $36.98 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CGON
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.